Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Similar short-term efficacy of oral levosulpiride and intravitreal ranibizumab in patients with diabetic macular oedema.

Eye (London, England)·2025

Same author

Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial.

Eye (London, England)·2023

Same author

Electric Shock Retinopathy: Case Report of a Late Retinal Manifestation.

Journal of vitreoretinal diseases·2023

Same author

Association Between First- and Third-Month Responses to Intravitreal Ranibizumab for Diabetic Macular Edema.

Journal of vitreoretinal diseases·2023

Same author

Chorioretinal Findings in a Patient with New-Onset Systemic Lupus Erythematosus and Antiphospholipid Syndrome after Stillbirth Associated with Pre eclampsia.

Ocular immunology and inflammation·2023

Same author

Preventable risk factors for type 2 diabetes can be detected using noninvasive spontaneous electroretinogram signals.

PloS one·2023

Search research articles

Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Progressive Massive Choroidal Neovascularization, an Aggressive Phenotype: Case Report.

Renata García-Franco^1,2,3, Marlon García-Roa^1,2, Roberto Cárdenas-Almagro⁴

¹Retina Department, Instituto de La Retina Del Bajío, INDEREB, Santiago de Querétaro, Mexico.

Case Reports in Ophthalmology

|August 11, 2022

Summary

This summary is machine-generated.

This study presents two cases of aggressive choroidal neovascularization, a severe form of wet age-related macular degeneration, leading to significant vision loss despite treatment.

Keywords:

Age-related macular degeneration Choroidal neovascularization Polypoidal choroidal vasculopathy

More Related Videos

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Related Experiment Videos

Last Updated: Sep 2, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Area of Science:

Ophthalmology
Retinal Diseases
Neovascularization Studies

Background:

Choroidal neovascularization (CNV) is a major cause of vision loss, often associated with age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV).
Aggressive phenotypes of CNV can present with severe hemorrhage and exudation, posing treatment challenges.

Observation:

Two cases of elderly women with severe, aggressive CNV phenotypes are detailed.
One patient experienced extensive subretinal hemorrhage and fibrosis, progressing to light perception visual acuity post-treatment.
The second patient showed lesion enlargement despite anti-VEGF injections and photodynamic therapy, ultimately resulting in no light perception.

Findings:

The reported cases represent an aggressive extreme of CNV, characterized by massive hemorrhage and exudation.
These findings highlight a rare phenotype that can affect both posterior pole and peripheral retina.
Treatment resistance and rapid progression were noted in both cases.

Implications:

Understanding this aggressive CNV phenotype is crucial for managing severe cases of wet AMD and PCV.
Further research into novel therapeutic strategies may be needed for such extreme presentations.
Early recognition and management of aggressive CNV could potentially improve outcomes, though challenges remain.